The Analysis Of Treatment Schizophrenia By Aripiprazole And Olanzapine

Objective: To compare between Aripiprazole and Olanzapine in treatment, sideeffects and the the change of blood glucose, blood fats, weight and life quality onschizophrenia.Methods:200patients were recruited from those who was diagnosed withschizophrenia by CCMD-3criteria. The patients were randomly divided into2groups.The study group treated with Aripiprazole were missing2cases, the control grouptreated with Olanzapine were missing3cases. The two groups were treated for8weeks. Examined the EKG, fasting blood glucose, cholesterol, triglyceride, weightand life quality before treatment, after treatment for four-weeks and eight-weeks. Toassess the efficacy with positive and negative symptoms scale (PANSS). To assess theadverse reactions with the Treatment Emergent Symptom Scale (TESS) and tomeasure the quality of life with the WHOQOL-BREF. All database were establishedin excel and analyzed by statistical analysis software SPSS13.0. Groups werecompared using independent sample t test. To analysis the circumstance before andafter treatment using repeated measurement ANOVA.Results: The PANSS factors and total score were significantly reduced aftertreatment.(The study group F=3.32,0.01＜P＜0.05；The control group F=3.48,0.01＜P＜0.05), but the comparison between two groups had no significant difference (P＞0.05). The TESS score had significant difference in two groups after four-weekstreatment and eight-weeks treatment (The study group t=4.306，P＜0.01; The controlgroup t=4.64，P＜0.01). The main adverse reactions of Aripiprazole group wereinsomnia, headache and dizziness, while that of Olanzapine group were the increaseof weight and blood glucose. The cholesterol level in Aripiprazole group wassignificant lower than that of the Olanzapine group at the end of the four-weekstreatment and eight-weeks treatment (After four-weeks treatment F=3.235,0.01＜P＜0.05; After eight-weeks treatment F=5.014, P＜0.01). The low densitylipoprotein(LDL) level in Aripiprazole group was significant lower than that of the Olanzapine group (After four-weeks treatment F=3.124,0.01＜P＜0.05; Aftereight-weeks treatment F=4.718, P＜0.01).The high density lipoprotein(HDL) level inAripiprazole group was significant higher than that of the Olanzapine group afterfour-weeks treatment (F=5.138, P＜0.01). The fasting blood-glucose level inAripiprazole group was significant lower than that of the Olanzapine group at the endof eight-weeks treatment (F=3.698，0.01＜P＜0.05). The weight in Aripiprazolegroup was no significant different between before and after treatment（F=1.203，P≥0.05）. The weight in Olanzapine group was significant higher after treatment（F=5.326，P＜0.01）.The weight of two groups were no significant different beforetratment（t=0.147，P≥0.05）,while the weight of Aripiprazole group was significantlower than that of Olanzapine group after four-weeks treatment(t=2.138，0.01＜p＜0.05)and eight-weeks treatmen（tt=3.878，P＜0.01）.Life quality scores of two groupswere significant improved after treatment(0.01＜p＜0.05或p＜0.01), while lifequality scores were no significant different between two groups after four-weekstreatment and eight-weeks treatment（p＞0.05）.Conclusion: The Aripiprazole and Olanzapine can treat schizophrenia efficientlywith little adverse reaction. The Aripiprazole have little effect on blood glucose andblood fats, especially suitable for the obesity, high blood lipids, high blood glucoseand young unmarried person. The Aripiprazole and olanzapine can improve the lifequality of schizophrenia patients.